Tooth dentin defects reflect genetic disorders affecting bone mineralization

Several genetic disorders affecting bone mineralization may manifest during dentin mineralization. Dentin and bone are similar in several aspects, especially pertaining to the composition of the extracellular matrix (ECM) which is secreted by well-differentiated odontoblasts and osteoblasts, respectively. However, unlike bone, dentin is not remodelled and is not involved in the regulation of calcium and phosphate metabolism. In contrast to bone, teeth are accessible tissues with the shedding of deciduous teeth and the extractions of premolars and third molars for orthodontic treatment. The feasibility of obtaining dentin makes this a good model to study biomineralization in physiological and pathological conditions. In this review, we focus on two genetic diseases that disrupt both bone and dentin mineralization. Hypophosphatemic rickets is related to abnormal secretory proteins involved in the ECM organization of both bone and dentin, as well as in the calcium and phosphate metabolism. Osteogenesis imperfecta affects proteins involved in the local organization of the ECM. In addition, dentin examination permits evaluation of the effects of the systemic treatment prescribed to hypophosphatemic patients during growth. In conclusion, dentin constitutes a valuable tool for better understanding of the pathological processes affecting biomineralization.

► Several genetic disorders affecting bone mineralization such as osteogenesis imperfecta and hypophosphatemic rickets, also disturb dentin mineralization.
► Dentin and bone are similar in several aspects, especially pertaining to the composition of the extracellular matrix.
► In contrast to bone, dentin is not involved in calcium phosphate metabolism and is not remodelled during life.
► Dentin examination constitutes a valuable tool for better understanding of the pathological processes affecting biomineralization.
► Dentin examination permits evaluation of the effects of the systemic treatment prescribed to hypophosphatemic patients during growth.